Anti-Coagulants - Southern Europe

Southern Europe

The Anti-Coagulants market in Southern Europe is expected to witness a significant growth in revenue.
According to projections, the revenue is estimated to reach US$1.18bn by 2024.
Moreover, the market is anticipated to exhibit a steady annual growth rate of 7.06% (CAGR 2024-2029), leading to a market volume of US$1.66bn by 2029.
In terms of global comparison, United States is expected to generate the highest revenue, amounting to US$16,740.00m in 2024.
In Southern Europe, the demand for anti-coagulants is on the rise as the aging population increases the prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Southern Europe has been experiencing steady growth in recent years.

Customer preferences: Patients in Southern Europe are increasingly opting for non-vitamin K antagonist oral anticoagulants (NOACs) over traditional vitamin K antagonists (VKAs) due to their ease of use and lower risk of bleeding complications. Additionally, there is a growing demand for personalized medicine, with patients seeking tailored treatment plans based on their individual risk factors.

Trends in the market: Spain and Italy are the largest markets for anti-coagulants in Southern Europe, with both countries experiencing consistent growth in demand for NOACs. In Spain, the market is being driven by an aging population and an increase in the prevalence of atrial fibrillation. In Italy, the market is being bolstered by the rising incidence of venous thromboembolism and the growing use of NOACs in the treatment of cancer-related thrombosis.

Local special circumstances: In Greece, the anti-coagulants market is facing challenges due to the country's economic crisis. Many patients are unable to afford the cost of NOACs and are instead opting for cheaper VKAs. In Portugal, the market is being impacted by the country's strict reimbursement policies, which limit access to NOACs for certain patient populations.

Underlying macroeconomic factors: The Southern European market for anti-coagulants is being driven by several macroeconomic factors, including an aging population, the increasing prevalence of cardiovascular disease, and the growing use of NOACs in the treatment of cancer-related thrombosis. Additionally, the market is being impacted by the region's healthcare policies, which are focused on cost containment and the promotion of personalized medicine.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.